Clinical trial · Interventional
A Randomized Controlled Trial Evaluating the Effectiveness of a Novel Risk-Stratified Screening Strategy for Lung Cancer
NCT07078032CI-TRIAL-00092443not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A nationwide population-based multi-center RCT enrolling ≥60,000 eligible residents to compare screening effectiveness between risk-prediction-model-driven and traditional guideline-based high-risk lung cancer screening strategies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer Screening | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prediction Model Arm | Diagnostic Test | — | UNRESOLVED |
| Standard Screening Arm | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Prediction Model Arm
- description
- Lung Cancer Risk Prediction Model Arm
- interventionNames
- Diagnostic Test: Prediction Model Arm
- type
- ACTIVE_COMPARATOR
- label
- Standard Screening Arm
- description
- Traditional High-Risk Factors Arm
- interventionNames
- Diagnostic Test: Standard Screening Arm
Primary outcomes (1)
- measure
- Positive Predictive Value (PPV) of Screening Strategies
- timeFrame
- From enrollment through completion of diagnostic confirmation (up to 3 months post-screening)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 74 Years
Show eligibility criteria text
Inclusion Criteria: 1. Residents with local household registration residing continuously in the region for ≥3 years. 2. Aged 40-74 years at enrollment. Exclusion Criteria: 1. Prior diagnosis of lung cancer (histologically/cytologically confirmed) 2. Currently receiving active treatment for any malignancy. 3. Presence of severe comorbidities with life expectancy \<5 years 4. Participation in any lung cancer screening program within 5 years. 5. Functional dependency (ADL score ≤2) OR unwillingness to comply with protocol-required follow-up. 6. Declined to provide written informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.